Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer

Condition:   EGF-R Positive Non-Small Cell Lung Cancer Intervention:   Drug: Icotinib Sponsor:   Betta Pharmaceuticals Co.,Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials